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ABSTRACT 
The aim of this study was to investigate the efficacy of Intravitreal Injection of Bevacizumab (IVB) in patients with Central 
Serous Chorioretinopathy (CSC) compared to the control group, after four months of injection.  
In this study, 30 eyes of 30 patients with CSC, who were in the age range of 23 to 50 years old (70% male subject) were 
included. Eligible patients were randomly allocated to the intervention (n = 15) and control groups (n = 15). Patients in 
the intervention group received a single dose injection of bevacizumab (1.25 mg in 0.05 mL), while patients in the control 
group were followed-up during the same time interval, without any medical interventions. Corrected Distance Visual 
Acuity (CDVA) and Central Macular Thickness (CMT) were evaluated as the primary outcome measures at the four-month 
follow-up.  
There was no statistically significant difference between the intervention and control groups regarding their baseline 
characteristics. Corrected Distance Visual Acuity was improved significantly in the intervention group (P < 0.001), while 
this improvement was not observed in the control group. Furthermore, greater improvement of CDVA was detected in 
the IVB group compared to the patients without injection (P = 0.018). The CMT findings were in line with CDVA changes 
in both groups, revealing a significant reduction of CMT only in the intervention group (P < 0.001). Also, thinner central 
retina was found in the intervention group compared to the comparison group, at the four-month follow-up (P < 0.001).  
Based on the findings, bevacizumab could be effective for improvement of both anatomical and functional outcomes in 
patients with CSC. 
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INTRODUCTION
Central Serous Chorioretinopathy (CSC) is an idiopathic 
ocular disease that results from serous neurosensory 
retinal detachment at the posterior pole of the retina, 
due to the abnormal function of the Retinal Pigmented 
Epithelium (RPE) [1, 2]. Although choriocapillaris 
involvement is a primary pathologic ocular finding, yet 
fluid accumulation was shown to increase resulting from 
other abnormalities occurring in the RPE and choroidal 
tissue [3]. Although the main etiology of CSC is unknown, 
the recent literature has also shown increased choroidal 
thickness in such patients [1, 4]. 
Based on the literature, greater incidence of CSC has 
been reported among males in the age range of 25 to 55 
years old. Regarding geographical distribution, white 
people, Hispanics, and Asian individuals show high 
prevalence of CSC, while African Americans show the 
least prevalence of CSC. Subjects, who have been under 
major stressful conditions, or cases with high blood 
pressure, positive history of corticosteroids usage, and 
also pregnant females are at a higher risk of CSC [2, 5]. 
Complaints of sudden vision loss, micropsia, 
metamorphopsia, and difficulty in colour perception 
could be considered as common visual symptoms in 
these patients [2]. Clinical diagnosis could be achieved 
based on the ophthalmic examination and also retinal 
imaging, including Fluorescein Angiography (FAG) and 
Optical Coherence Tomography (OCT) [6, 7]. 
In this regard, various therapeutic modalities have been 
proposed by different reports, although some retina 
specialists believe that CSC could be resolved 
spontaneously in 80% to 90% of patients, during a period 
of three to four months, without any medical 
intervention [8]. However, in routine ophthalmic 
practice, laser photocoagulation, photodynamic therapy 
or intravitreal injection of anti-Vascular Endothelial 
Growth Factors (anti-VEGF), like Bevacizumab (IVB), have 
been proposed by other ophthalmologists [9, 10]. 
According to the literature, the level of both cytokinins 
and VEGFs are increased in patients with CSC [11], 
therefore, anti-VEGFs, including ranibizumab and 
bevacizumab, can be investigated in patients with CSC. It 
is evident that ranibizumab can penetrate in the retina 
with greater influence due to its smaller molecular size 
and higher binding affinity for VEGF, however, Kim et al. 
did not report on such findings [12]. In this regard, the 
positive effect of bevacizumab has been found in some 
clinical trials, revealing improvement in both functional 
and anatomical findings [13-18], however, it was not 
found to be effective for treatment of CSC in a meta- 
analysis by Chung et al. [19]. Although Park et al. [20] did 
not find any difference between cases injected with IVB 
and those, who were only followed-up without any 
treatment, they found that it could accelerate the 
spontaneous absorption of sub-retinal fluid and decrease 
the probability of degeneration of photoreceptor cells. 
In the present pilot Randomized Clinical Trial (RCT), the 
researchers aimed at investigating the efficacy of IVB 
injection in patients with CSC, compared to patients in 
the comparison group, after four months of injection. 
MATREIALS AND METHODS 
Participants 
In this pilot RCT, a total of 30 eyes of 30 patients, with 
CSC and an age range of 23 to 50 years old, were 
included. Sampling was performed among patients that 
had referred to the Alzahra Eye Hospital, Zahedan 
University of Medical Sciences, between January, 2015 
and April, 2017. The study adhered to the Deceleration of 
Helsinki and was approved by the Ethics Committee of 
Ophthalmic Research Center, affiliated to Zahedan 
University of Medical Sciences, Zahedan, Iran. This study 
was registered at IRCT.ir with registration number 
Irct2017041533448n1. 
All patients with a diagnosis of CSC and complaining of 
vision loss in the last three months were included. 
Patients with other ocular pathologies, significant 
cardiovascular or thromboembolic history or pregnant 
females, and cases with a history of previous treatment 
for CSC, were excluded from the investigation. Diagnosis 
was performed by a single retina specialist by 
interpretation of OCT images, demonstrating the 
neurosensory retinal elevation, and also FAG, presenting 
the focal leaks at the level of the RPE. The detailed study 
procedure was explained for all participants and an 
informed consent letter was obtained from them before 
any intervention. 
All patients underwent a comprehensive ophthalmic 
examination, including CDVA assessment, using the 
Snellen visual acuity chart at a distance of 6 m. Slit lamp 
examination and indirect ophthalmoscopy through 
dilated pupils by a non-contact 78-diopter lens were 
performed by an ophthalmologist. In addition, central 
macular thickness (CMT) was also measured using a 
Cirrus HD-OCT (Carl Zeiss Meditec, Dublin, CA). All 
examinations were performed at baseline and also 
repeated at the four-month follow-up for patients in 
both intervention and control groups.  
Thirty eligible eyes were randomly assigned to the IVB (n 
= 15) and control (n = 15) groups, so that patients in the 
intervention group received a single dose of IVB, under 
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standard conditions, while subjects in the comparison 
group were followed-up during the same time period 
without any medical interventions. 
In the operating room, a speculum was inserted after 
prepping and draping and also providing the topical 
anesthesia. In addition, sterilization of the ocular surface 
was performed using a solution of povidone iodine 5%. 
Thereafter, bevacizumab (1.25 mg in 0.05 mL, Avastin®; 
Roche, Basel, Switzerland) was prepared in a 27-gauge 
syringe and it was injected, supratemporaly, 4 mm 
posterior to the limbus. The location was depressed with 
an applicator and eyes were irrigated using a balanced 
salt solution (BSS; Plus, Alcon Laboratories, Ft. Worth, 
TX). All injected patients were recommended to apply 
the 0.3% ciprofloxacin, six hours per day and 0.1% 
betamethasone three hours per a day for a duration of 
10 days after the IVB injection.  
Main Outcome Measure 
The mean changes of CDVA and CMT on the fourth 
month follow-up compared to the baseline values were 
the primary outcomes. Furthermore, the difference of 
mean CDVA and CMT on the fourth month follow-up 
between the two groups were analysed as the secondary 
outcomes in this study. 
Sample Size 
To obtain a power of 80% and to detect a difference as 
large as 0.2 LogMAR between the two groups when the 
standard deviation (SD) of groups was believed to be 
0.19 [13], a sample of 15 in each group was needed. In 
this calculation, the statistical significance level was 
assumed to be 0.05. 
Randomization 
The permuted-block randomization method was used 
with a random length of block between two and six. The 
sequence of random allocation was generated by a 
computer program and concealed from the investigators.  
Blinding 
The visual examination and OCT measurement were 
conducted by a trained optometrist, who was masked 
regarding the randomization and the previous clinical 
findings. In addition, the biostatistician was blinded to 
the patients' treatment when statistical analysis was 
performed on the coded data. 
Statistical Analysis 
Data were presented with means, SDs, frequencies, and 
percentages. Baseline characteristics were compared by 
the Chi-Squared and Fisher’s exact test. To evaluate 
changes within groups, paired sample t-test was used. To 
compare the groups, independent sample t-test was 
used. Magnitude of difference was presented by mean 
difference and its 95% confidence interval. All statistical 
analysis was performed by the SPSS software (version 24, 
Armonk, NY: IBM Corp.). All tests were two sided and the 
significance level was assumed to be 0.05. 
 
Figure 1. Flowchart of the Present Study 
 
n: number; IVB: Intraviteal Bevacizumab 
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Table 1. Demographic Characteristics in both Intervention and Comparison Groups 
 Total Intervention Groups Comparison Groups P-value 
Age (y) 36.9 ± 6.76 37.2 ± 7.32 36.7 ± 6.4 0.833 * 
Age Median (range) 36 (23 to 50) 36 (23 to 50) 35 (28 to 50)  
Gender    0.427 † 
Male 21 (70.0%) 9 (60.0%) 12 (80.0%)  
Female 9 (30.0%) 6 (40.0%) 3 (20.0%)  
* based on Independent T-test. 
† based on Fisher Exact test. 
Data in table presented as Mean ± Standard Deviation (SD) or number (%). 
 
Table 2. Corrected Distance Visual Acuity (CDVA) at Baseline and Follow-up on the Fourth Month  
 Total Intervention Group Comparison 
Group 
Difference 95% Cl Lower 95% Cl Upper P-value* 
CDVA, baseline 
(LogMAR)  
0.4 ± 0.22 0.39 ± 0.13 0.4 ± 0.28 -0.01 ± 0.08 -0.172 0.16 0.928 
CDVA, Month 4 
(LogMAR) 
0.2 ± 0.2 0.11 ± 0.13 0.29 ± 0.22 -0.18 ± 0.07 -0.32 -0.05 0.009 
Changes of CDVA -0.2 ± 0.21 -0.29 ± 0.18 -0.11 ± 0.21 -0.18 ± 0.07 -0.32 -0.03 0.018 
P-value†  < 0.001 0.059     
CDVA: Corrected Distance Visual Acuity; LogMAR: logarithm of the minimum angle of resolution; CI: confidence interval 
*Based on independent T-test 
† Based on Paired test;  
P values less than 0.05 considered significant. Data in table presented as Mean ± Standard Deviation (SD) 
 
Table 3. Central Macular Thickness (CMT) at Baseline and Follow-up of Fourth Month  
 Total Intervention Group Comparison Group Difference 95% Cl Lower 95% Cl Upper P-value * 
CMT, baseline 
(µm) 
396 ± 83 408 ± 91 384± 75 24 ± 30 -39 86 0.442 
CMT, month 4 
(µm) 
300 ± 80 249 ± 42 350 ± 78 -100 ± 23 -147 -53 < 0.001 
Changes of CMT -97 ± 104 -159 ± 98 -35 ± 68 -124 ± 31 -187 -61 < 0.001 
P-value †  < 0.001 0.067     
CI: confidence interval, µm: micrometer 
* Based on independent T-test 
† Based on Paired test. 
P values less than 0.05 considered significant. Data in table presented as Mean ± Standard Deviation (SD) 
 
RESULTS 
In this pilot RCT, a total of 30 eligible patients (male, 
70%) with a clinical diagnosis of CSC and a mean ± SD age 
of 36.93±6.76 years were included. All enrolled patients 
completed their follow-up examination and there was no 
patient that refused to continue participation, as shown 
in Figure 1. 
Demographic characteristics of patients in both 
intervention and control groups are presented in Table 1. 
As indicated, there was no statistically significant 
difference between intervention and control groups in 
terms of age and gender.  
Mean CDVA at both time points of baseline and fourth 
month follow-up are summarized in Table 2. The mean 
baseline CDVA was 0.39 ± 0.13 LogMAR in the 
intervention group, which was improved to 0.11 ± 0.13 
LogMAR on the fourth month (P < 0.001), while this 
improvement was not observed in the control group (P = 
0.059). In addition, it is obvious that higher mean CDVA 
(P = 0.009) and more significant improvement (P = 0.018) 
were detected in the intervention group compared with 
the control group. However, this difference was a bit 
lower than the clinical significant threshold (0.18 versus 
0.20). 
Regarding the analysis of CMT (Table 3), the current 
findings were in line with CDVA outcomes, which showed 
 
 
Med Hypothesis Discov Innov Ophthalmol. 2018; 7(4)  
 
180 EFFECT OF INTRAVITREAL BEVACIZUMAB IN CSCR 
significant reduction of CMT only in the IVB group (P < 
0.001) and also thinner CMT in cases, who were injected 
by IVB compared to patients without any injection at the 
fourth month follow-up (249 ± 42 µm versus 350 ± 78 
µm, P < 0.001). In addition, more reduction of CMT 
occurred in the intervention group compared to the 
control group (159 ± 98 µm versus 35 ± 68 µm, P < 
0.001). Furthermore, no ocular complication, including 
extensive haemorrhage, increase of Intraocular Pressure 
(IOP), and ocular inflammation was observed during 
and/or after the injection. 
DISCUSSION 
The physiopathology of CSC has yet to be fully 
understood and it is believed that multiple causes and 
mechanisms are found in such patients, which eventually 
lead to hyperdynamic choroidal circulation and choroidal 
vascular hyperpermeability [21]. In these patients, 
breakdown of RPE barriers occurs due to increased 
hydrostatic choroidal pressure, which causes subsequent 
leakage of the fluid in the sub-retinal space [22]. 
Furthermore, CSC has been taken in consideration in the 
past few years by investigations of different treatment 
modalities for these patients, however, a clear scheme 
has not been fully elucidated [23]. 
Although the efficacy and favorable visual outcomes of 
Photodynamic Therapy (PDT) have been shown in the 
treatment of patients with CSC, it can also be associated 
with complications, including foveal thinning, RPE 
atrophy, choriocapillaris ischemia, Choroidal 
Neovascularization (CNV), and transient abnormal 
response on multifocal Electroretinography (mfERG) [24]. 
In addition, less accessibility and high expenses of PDT 
can be considered as other limitations of PDT therapy for 
patients with CSC [25]. Furthermore, greater safety and 
efficacy of IVB have been shown compared with PDT 
therapy [26]. 
Furthermore, historical thermal (argon) laser 
photocoagulation is another proposed therapeutic 
modality for patients with CSC, which may accelerate the 
resolution of the associated neurosensory detachment 
[8]. Based on the literature, significant adverse effects, 
including permanent scotoma, enlargement of RPE scar, 
secondary laser-induced CNV formation, and inadvertent 
foveal photocoagulation may occur [13, 27]. In addition, 
Subthreshold Diode Laser Micropulse (SDM) 
photocoagulation is another suggestion, the safety and 
efficacy of which has been reported in the management 
of patients with CSC and the superiority of SDM was 
detected compared with IVB in the study of Koss et al. 
[28]. 
Based on the literature, it has been demonstrated that 
the Vascular Endothelial Growth Factor (VEGF) level in 
aqueous humour of patients with CSC is higher compared 
to the normal population [29]. In this regard, other 
studies have concluded that VEGF may contribute to the 
pathogenesis of CSC and also be involved in fluid leakage 
in these patients, therefore, intravitreal anti-VEGF 
therapy has been studied by various research groups [13-
16, 19, 20, 26, 30, 31]. The current researchers believe 
that VEGF can be considered as a "vascular permeability 
factor" and bevacizumab may reduce choroidal 
hyperpermeability due to the reduction of VEGF level 
and reverse choroidal changes due to its anti-
permeability properties. 
In this pilot RCT, the therapeutic effect of IVB was 
investigated on both functional and anatomical 
characteristics of patients with CSC. This research 
determined that CDVA was improved significantly in the 
intervention group, while it was not observed in the 
control group. Greater improvement of CDVA was 
detected in the IVB group compared to patients in the 
control group. However, this difference was a bit lower 
than the clinical significant threshold (0.18 versus 0.20). 
In addition, CMT findings were in line with CDVA changes 
in both groups, revealing the significant reduction of CMT 
only in the intervention group. Also, thinner central 
retina was found in the intervention group compared to 
patients, who were in the control group at the fourth 
month follow-up. 
Although the safety and efficacy as well as both 
anatomical and functional benefits of IVB in the 
treatment of CSC have been shown in different case 
series [13, 30, 31], these findings need to be validated 
further by a RCT with consideration of a comparison 
group. Recent studies were mostly uncontrolled 
prospective case series and were conducted on a small 
sample size. In addition, Park et al. [20] did not find any 
difference between cases injected by IVB and those, who 
were only followed-up without any treatment; they 
found that IVB injection could accelerate the 
spontaneous absorption of sub-retinal fluid and decrease 
the probability of the degeneration of the photoreceptor 
cells.  
On the other hand, a lack of positive effect of IVB on CSC 
patients was reported in a meta-analysis by Chung et al. 
[19], which could be attributed to the clinical 
heterogeneity of the selected four comparative studies. 
One of the reasons for heterogeneity of this study is the 
consideration of both acute and chronic CSC eyes, which 
may show different responses to treatment. Usage of 
different concentrations of bevacizumab and lack of a 
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unique control group could be considered as other 
heterogeneity factors. In addition, lack of significant 
effectiveness of IVB on patients with CSC could be 
attributed to the study design and/or small number of 
cases in the study by Lim et al. [32].  
Akhlaghi et al. [33] did not find the effectiveness of IVB 
on CSC patients in the short term follow-up of three 
months, while Semeraro et al. [34] found it as an 
effective treatment in longer follow-up of nine months. 
All the patients in both intervention and control groups 
were followed up for four months due to the fact that 
foveal photoreceptor atrophy in patients with CSC might 
occur up to four months after the onset of symptoms 
[35]. Also, the spontaneous treatment of CSC in a 
duration of three months has been reported [8], 
therefore, it was not ethical to follow-up the subjects in 
the control group without any intervention for a longer 
time. 
CONCLUSION 
Although bevacizumab seems to be effective in 
improvement of both anatomical and functional visual 
outcomes in patients with CSC, more investigations with 
a larger sample size and longer follow-up are 
recommended in order to overcome the possible 
limitations of the current clinical trial. 
DISCLOSURE 
Ethical issues have been completely observed by the 
authors. All named authors meet the International 
Committee of Medical Journal Editors (ICMJE) criteria for 
authorship for this manuscript, take responsibility for the 
integrity of the work as a whole, and have given their 
final approval for the version to be published. No conflict 
of interest has been presented. 
REFERENCES 
1. Liegl R, Ulbig MW. Central serous chorioretinopathy. 
Ophthalmologica. 2014;232(2):65-76. doi: 
10.1159/000360014 pmid: 24776999 
2. Carvalho-Recchia CA, Yannuzzi LA, Negrao S, Spaide RF, 
Freund KB, Rodriguez-Coleman H, et al. Corticosteroids and 
central serous chorioretinopathy. Ophthalmology. 
2002;109(10):1834-7. pmid: 12359603 
3. Meyerle CB, Spaide RF. Central serous chorioretinopathy. 
In: Albert DM, Miller JW, Azar DT, Blodi BA, editors. Albert 
and Jakobiec's Principles and Practice of Ophthalmology. 
Philadelphia: Saunders; 2008. 
4. Arora S, Pyare R, Sridharan P, Arora T, Thakar M, Ghosh B. 
Choroidal thickness evaluation of healthy eyes, central 
serous chorioretinopathy, and fellow eyes using spectral 
domain optical coherence tomography in Indian population. 
Indian J Ophthalmol. 2016;64(10):747-51. doi: 
10.4103/0301-4738.194999 pmid: 27905337 
5. Haimovici R, Koh S, Gagnon DR, Lehrfeld T, Wellik S, Central 
Serous Chorioretinopathy Case-Control Study G. Risk factors 
for central serous chorioretinopathy: a case-control study. 
Ophthalmology. 2004;111(2):244-9. doi: 10.1016/j.ophtha. 
2003.09.024 pmid: 15019370 
6. Chatziralli I, Kabanarou SA, Parikakis E, Chatzirallis A, Xirou 
T, Mitropoulos P. Risk Factors for Central Serous 
Chorioretinopathy: Multivariate Approach in a Case-Control 
Study. Curr Eye Res. 2017;42(7):1069-73. doi: 
10.1080/02713683.2016.1276196 pmid: 28306346 
7. Imamura Y, Fujiwara T, Margolis R, Spaide RF. Enhanced 
depth imaging optical coherence tomography of the 
choroid in central serous chorioretinopathy. Retina. 
2009;29(10):1469-73. doi: 10.1097/IAE.0b013e3181be0a83 
pmid: 19898183 
8. Ross A, Ross AH, Mohamed Q. Review and update of central 
serous chorioretinopathy. Curr Opin Ophthalmol. 
2011;22(3):166-73. doi: 10.1097/ICU.0b0 13e3283459826 
pmid: 21427570 
9. Salehi M, Wenick AS, Law HA, Evans JR, Gehlbach P. 
Interventions for central serous chorioretinopathy: a 
network meta-analysis. Cochrane Database Syst Rev. 
2015(12):CD011841. doi: 10.1002/14651858.CD0118 
41.pub2 pmid: 26691378 
10. Ober MD, Yannuzzi LA, Do DV, Spaide RF, Bressler NM, 
Jampol LM, et al. Photodynamic therapy for focal retinal 
pigment epithelial leaks secondary to central serous 
chorioretinopathy. Ophthalmology. 2005;112(12):2088-94. 
doi: 10.1016/j.ophtha.2005.06 .026 pmid: 16325707 
11. Jung SH, Kim KA, Sohn SW, Yang SJ. Cytokine levels of the 
aqueous humour in central serous chorioretinopathy. Clin 
Exp Optom. 2014;97(3):264-9. doi: 10.1111/cxo.12125 
pmid: 24417755 
12. Kim M, Lee SC, Lee SJ. Intravitreal ranibizumab for acute 
central serous chorioretinopathy. Ophthalmologica. 
2013;229(3):152-7. doi: 10.1159/00 0345495 pmid: 
23257663 
13. Lim JW, Kim MU. The efficacy of intravitreal bevacizumab 
for idiopathic central serous chorioretinopathy. Graefes 
Arch Clin Exp Ophthalmol. 2011;249(7):969-74. doi: 
10.1007/s00417-010-1581-9 pmid: 21140161 
14. Mehany SA, Shawkat AM, Sayed MF, Mourad KM. Role of 
Avastin in management of central serous 
chorioretinopathy. Saudi J Ophthalmol. 2010;24(3):69-75. 
doi: 10.1016/j.sjopt.2010.03.002 pmid: 23960879 
15. Entezari M, Ramezani A, Yaseri M. Intravitreal bevacizumab 
for treatment of refractory central serous 
choroidoretinopathy. Korean J Ophthalmol. 2012;26(2):139-
42. doi: 10.3341/kjo.2012.26.2.139 pmid: 22511842 
16. Iacono P, Battaglia Parodi M, Falcomata B, Bandello F. 
Central Serous Chorioretinopathy Treatments: A Mini 
Review. Ophthalmic Res. 2015;55(2):76-83. doi: 
10.1159/000441502 pmid: 26619293 
17. Artunay O, Yuzbasioglu E, Rasier R, Sengul A, Bahcecioglu H. 
Intravitreal bevacizumab in treatment of idiopathic 
 
 
Med Hypothesis Discov Innov Ophthalmol. 2018; 7(4)  
 
182 EFFECT OF INTRAVITREAL BEVACIZUMAB IN CSCR 
persistent central serous chorioretinopathy: a prospective, 
controlled clinical study. Curr Eye Res. 2010;35(2):91-8. doi: 
10.3109/02713680903428306 pmid: 20136418 
18. Aydin E. The efficacy of intravitreal bevacizumab for acute 
central serous chorioretinopathy. J Ocul Pharmacol Ther. 
2013;29(1):10-3. doi: 10.1089/jop.20 12.0072 pmid: 
22925113 
19. Chung YR, Seo EJ, Lew HM, Lee KH. Lack of positive effect of 
intravitreal bevacizumab in central serous 
chorioretinopathy: meta-analysis and review. Eye (Lond). 
2013;27(12):1339-46. doi: 10.1038/eye.2013 .236 pmid: 
24202051 
20. Park SU, Lee SJ, Kim M. Intravitreal anti-vascular endothelial 
growth factor versus observation in acute central serous 
chorioretinopathy: one-year results. Korean J Ophthalmol. 
2014;28(4):306-13. doi: 10.3341/kjo.2014.28.4.306 pmid: 
25120339 
21. Guyer DR, Yannuzzi LA, Slakter JS, Sorenson JA, Ho A, Orlock 
D. Digital indocyanine green videoangiography of central 
serous chorioretinopathy. Arch Ophthalmol. 
1994;112(8):1057-62. pmid: 8053819 
22. Pryds A, Sander B, Larsen M. Characterization of subretinal 
fluid leakage in central serous chorioretinopathy. Invest 
Ophthalmol Vis Sci. 2010;51(11):5853-7. doi: 
10.1167/iovs.09-4830 pmid: 20505211 
23. Alkin Z, Osmanbasoglu OA, Ozkaya A, Karatas G, Yazici AT. 
Topical nepafenac in treatment of acute central serous 
chorioretinopathy. Med Hypothesis Discov Innov 
Ophthalmol. 2013;2(4):96-101. pmid: 24822228 
24. Chan WM, Lam DS, Lai TY, Tam BS, Liu DT, Chan CK. 
Choroidal vascular remodelling in central serous 
chorioretinopathy after indocyanine green guided 
photodynamic therapy with verteporfin: a novel treatment 
at the primary disease level. Br J Ophthalmol. 
2003;87(12):1453-8. pmid: 14660450 
25. Tzekov R, Lin T, Zhang KM, Jackson B, Oyejide A, Orilla W, et 
al. Ocular changes after photodynamic therapy. Invest 
Ophthalmol Vis Sci. 2006;47(1):377-85. doi: 
10.1167/iovs.05-0838 pmid: 16384988 
26. Lee JY, Chae JB, Yang SJ, Kim JG, Yoon YH. Intravitreal 
bevacizumab versus the conventional protocol of 
photodynamic therapy for treatment of chronic central 
serous chorioretinopathy. Acta Ophthalmol. 
2011;89(3):e293-4. doi: 10.1111/j.1755-3768.2009.01 835.x 
pmid: 20346078 
27. Robertson DM, Ilstrup D. Direct, indirect, and sham laser 
photocoagulation in the management of central serous 
chorioretinopathy. Am J Ophthalmol. 1983;95(4):457-66. 
pmid: 6682293 
28. Koss MJ, Beger I, Koch FH. Subthreshold diode laser 
micropulse photocoagulation versus intravitreal injections 
of bevacizumab in the treatment of central serous 
chorioretinopathy. Eye (Lond). 2012;26(2):307-14. doi: 
10.1038/eye.2011.282 pmid: 22079961 
29. Lim JW, Kim MU, Shin MC. Aqueous humor and plasma 
levels of vascular endothelial growth factor and interleukin-
8 in patients with central serous chorioretinopathy. Retina. 
2010;30(9):1465-71. doi: 10.1097/IAE.0b013e3181d8e7fe 
pmid: 20526231 
30. Torres-Soriano ME, Garcia-Aguirre G, Kon-Jara V, Ustariz-
Gonzales O, Abraham-Marin M, Ober MD, et al. A pilot 
study of intravitreal bevacizumab for the treatment of 
central serous chorioretinopathy (case reports). Graefes 
Arch Clin Exp Ophthalmol. 2008;246(9):1235-9. doi: 
10.1007/s00417-008-0856-x pmid: 18523796 
31. Gregori-Gisbert I, Aguirre-Balsalobre F, Garcia-Sanchez J, 
Leon-Salvatierra G, Mengual-Verdu E, Hueso-Abancens JR. 
[Recurrent and chronic central serous chorioretinopathy. 
Retina thickness evaluation one month after intravitreal 
bevacizumab injection]. Arch Soc Esp Oftalmol. 
2011;86(12):407-11. doi: 10.1016/j.oftal.2011.05.021 pmid: 
22117740 
32. Lim JW, Ryu SJ, Shin MC. The effect of intravitreal 
bevacizumab in patients with acute central serous 
chorioretinopathy. Korean J Ophthalmol. 2010;24(3):155-8. 
doi: 10.3341/kjo.2010.24.3.155 pmid: 20532141 
33. Akhlaghi MR, Nasrollahi C, Namgar SM, Kianersi F, Dehghani 
AR, Arefpour R. Effect of Intravitreal Injection of 
Bevacizumab on Acute Central Serous Chorioretinopathy 
Patients Who Visited Feiz Hospital during 2014-2015 Period. 
Adv Biomed Res. 2017;6:125. doi: 10.4103/abr.abr_193_15 
pmid: 29142888 
34. Semeraro F, Romano MR, Danzi P, Morescalchi F, 
Costagliola C. Intravitreal bevacizumab versus low-fluence 
photodynamic therapy for treatment of chronic central 
serous chorioretinopathy. Jpn J Ophthalmol. 
2012;56(6):608-12. doi: 10.1007/s10384-012-0162-3 pmid: 
22915299 
35. Gass JD. Pathogenesis of disciform detachment of the 
neuroepithelium. Am J Ophthalmol. 1967;63(3):Suppl:1-
139. pmid: 6019308 
 
